Disseminated Herpes Zoster with Decreased CD4 Counts in a HIV-Infected Patient

Linxi Zeng 1, Sen Feng 1, Lulu Yao 1, Jiaqing Zhao 1, Guoqiang Zhang 1,2

1Department of Dermatology, The First Hospital of Hebei Medical University, Shijiazhuang City, Hebei Province, People’s Republic of China;
2Candidate Branch of National Clinical Research Center for Skin Diseases, Shijiazhuang, People’s Republic of China

Correspondence: Guoqiang Zhang, The First Hospital of Hebei Medical University, 89 Donggang Road, Yuhua District, Shijiazhuang City, Hebei Province, People’s Republic of China, Email zlx090702@163.com

Abstract: Herpes zoster is typically a blister rash involving a single skin group, caused by the reactivation of primary varicella zoster virus infection. Disseminated herpes zoster refers to the presence of more than 20 small blisters outside the primary or adjacent skin, which is rare and usually occurs in individuals with weakened immune function. This case described a patient diagnosed with disseminated herpes zoster, with a decrease in CD4 count (379 cells/mm3) and certain skin lesions. He was subsequently screened positive for HIV. Also, we summarized other studies on the CD4 value of HIV patients with herpes zoster. Overall, for herpes zoster patients with decreased CD4 levels and certain skin manifestations, such as diffuse, ulcerative, or pustular lesions, clinicians should be aware of HIV infection.

Keywords: disseminated herpes zoster, CD4, HIV infection

Introduction

Varicella zoster virus (VZV) is a double-stranded DNA virus that causes varicella, its primary infection, and herpes zoster in recurrent infection. After initial exposure, VZV will lurk in the dorsal root ganglion. When immunity decreases, varicella shingles virus (VZV) will reactivate from its dormant state, resulting in herpes zoster.1 It usually manifests as a unilateral skin distributed blister rash associated with pain. Disseminated herpes zoster is usually defined as a systemic rash with more than 20 skin vesicles within a week after the onset of typical skin lesions. Disseminated herpes zoster is rare and occurs mainly in the elderly or infirm.2

Acquired immune deficiency syndrome (AIDS) is a very harmful infectious disease, caused by human immunodeficiency virus (HIV) infection. HIV can directly attack CD4+ cells that play an important role in the human immune system. After infection, it can cause complete or partial loss of immune system function.3 Today, the disease burden of HIV is high, and the late diagnosis of HIV will increase the incidence rate and mortality. Early identification can initiate appropriate treatment as early as possible, thereby reducing the risk of opportunistic infections and transmission.4

Herpes zoster, as an opportunistic infection associated with HIV infection, may be the initial or early manifestation of HIV infection.5 Here, we report a case of disseminated herpes zoster patient who was subsequently found to be HIV positive. Notably, some characteristics of this patient may serve as predictive factors for HIV infection.

Case Description

A 77-year-old male was admitted to our dermatology clinic with a 1-week history of rash on the right side of his head and face, accompanied by pain and numbness. The rash gradually spread to the chest, back and limbs and his condition worsened. The patient was diagnosed with diabetes 10 years ago and was treated with gliclazide and metformin. He underwent cataract surgery 10 years ago and was diagnosed with neurological deafness 7 years ago, with almost complete loss of hearing. In addition, the patient denied history of sexual contact. Physical examination manifested that the right side of the head and face was swollen, and a large amount of erythema and dark purple spots were along the right mandibular...
nerve in a zonal distribution. Above the erythema and dark purple spots were clustered vesicles, pustules, and papules ranging from millet to rice. Some of them were ulcerated and exuded, and dark red crusts were on the surface. Apart from the primary site on the right side of his head and face, there were over 20 rice grain sized blisters and pustules scattered throughout the body, including the chest, back, and limbs, with blood scabs on some surfaces. Thus, he was diagnosed with disseminated herpes zoster (Figure 1). Laboratory test showed that CD4 T cells counted 16.49%, 379 cells/mm³ (500–1500 cells/mm³), CD8 T cells counted 56.15%, 1291 cells/mm³ (320–1250 cells/mm³) and the ratio of CD4 to CD8 was 0.29 (1.4–2.0). Subsequently, it was found that his HIV antibody was positive in the serum.

The patient was treated with penciclovir to fight against the virus, placental polypeptides to enhance immunity, oral mecobalamin tablets and vitamin B1 tablets to provide nutrition for nerves, gabapentin capsules and lovenadine sustained-release tablets to relieve pain. Moreover, he began receiving antiretroviral therapy (ART) and regular monitoring. On the 15th day, the patient’s symptoms of rash and pain significantly improved, and the number of CD4 +T cells increased to 465/uL. It demonstrated that the right side of the head and face was slightly swollen, and there were only a small amount of erythema and dark purple spots along the nerve, with dark red scabs on the surface.

Discussion

HIV can invade the immune system and reduce the immunity of patients. These patients are more prone to opportunistic infections, with some common infections including pneumoconiosis pneumonia and candidiasis.6 Moreover, there are other manifestations of HIV infection, which may become a predictor of such patients. This case provided an HIV infected patient with herpes zoster as the first manifestation. Given his age, the patient was at a higher risk of developing herpes zoster. But we noticed that his symptoms of rash and pain significantly improved, and the number of CD4 +T cells increased to 465/uL. It demonstrated that the right side of the head and face was slightly swollen, and there were only a small amount of erythema and dark purple spots along the nerve, with dark red scabs on the surface.

CD4+ T lymphocyte, as a key component of the immune system, are primary target cells for HIV. Generally, the number of CD4 cells will decline with the progress of AIDS, reflecting the severity of the disease.8 Furthermore, the CD4 cells count may be a clue for the onset of herpes zoster in HIV patients. Marshall et al9 found that a lower CD4 cell count is more closely related to the incidence of herpes zoster in HIV population. Among the HIV-infected women, using CD4 (750 cells/uL) as a reference, CD4 500–749 cells/uL was 1.43 (95% CI 0.86–2.37), CD4 350–499 cells/uL was 2.07
(95% CI 1.27–3.38), CD4 200–349 cells/μL was 2.72 (95% CI 1.66–4.46), and CD4 200 cells/μL was 3.16 (95% CI 1.92–5.18). Three studies from different countries have found that the average CD4 count of patients with HIV infection and herpes zoster decreased, with 152, 128 and 261, respectively.10–12 According to data from Thailand, the CD4 200–499/μL subgroup and CD4<200/μL subgroup had significantly more herpes zoster than the CD4≥500/μL subgroup in HIV population.13 A survey in China recorded 185 patients with HIV and herpes zoster, and found that there were significantly more patients with CD<200 than those with CD≥200 (P<0.05).14 A study in Turkey found that there was a significant correlation between herpes zoster and low CD4 cell count (P<0.05).15 However, a prospective cohort study from Uganda showed no significant correlation between CD4 cell count and herpes zoster in HIV patients.16 Anna et al17 reported 146 HIV infected people, 30 of whom developed herpes zoster. It showed that there was no significant difference in CD4 levels between individuals with and without herpes zoster.

Specifically, there are studies that separately investigate the incidence of disseminated herpes zoster in HIV patients. An observational study in Colombia found that the CD4 count of HIV patients with disseminated herpes zoster was between 200 and 499 cells/mm3, which was statistically significant (p=0.04). It was pointed out that the incidence of disseminated herpes zoster increased with the decrease of CD4 T cells.18 Catherine et al19 reported a middle-aged woman without other HIV risk factors. She had severe, disseminated, persistent herpes zoster with a low CD4 T cell count <200/μL. She was later found to be HIV positive. However, Pooja et al20 reported disseminated herpes zoster with increased CD4 counts in 3 HIV-infected patients (case1=762, case2=420, case3=540). More studies and cases recording the CD4 count in patients with herpes zoster and HIV are summarized in Tables 1 and 2. Overall, most studies have shown that the count of CD4 has certain significance in the diagnosis of HIV patients with herpes zoster, promoting clinicians to screen for HIV in patients with decreased CD levels.

Meanwhile, the skin lesions characteristics of herpes zoster in HIV patients can also provide some clues. Herpes zoster in HIV-infected patient is usually very severe and can cause epidermal ulcers and necrosis, resulting in more severe scarring. It can diffuse and may have a prolonged course and poor prognosis.28 Philip et al29 described a 45-year-old man with HIV infection who was initially presented with herpes zoster. The patient’s characteristics are as follows: several adjacent skin blisters, multiple vesicles and pustules merging to form large blisters, extensive necrosis accompanied by scab formation, and very painful skin lesions. It should be noted that disseminated herpes zoster is more

<table>
<thead>
<tr>
<th>Author</th>
<th>Year</th>
<th>Area</th>
<th>Type</th>
<th>Mean Age/Gender</th>
<th>Population</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ozlem15</td>
<td>2015</td>
<td>Turkey</td>
<td>Retrospective</td>
<td>38.3 38.4 36</td>
<td>Man:67.7% Man:67.7% Man:63.4% 18 HIV-infected patients with herpes zoster 67 HIV-infected patients with herpes zoster 108 HIV-infected patients with herpes zoster</td>
<td></td>
</tr>
<tr>
<td>Yu-Ye14</td>
<td>2019</td>
<td>China</td>
<td>Retrospective</td>
<td>38.4 38.4 36</td>
<td>Man:67.7% Man:67.7% Man:63.4% 185 HIV-infected patients with herpes zoster 67 HIV-infected patients with herpes zoster 108 HIV-infected patients with herpes zoster</td>
<td></td>
</tr>
<tr>
<td>Xiao-jie11</td>
<td>2011</td>
<td>China</td>
<td>Retrospective</td>
<td>36</td>
<td>Man:63.4% 67 HIV-infected patients with herpes zoster</td>
<td></td>
</tr>
<tr>
<td>Josephine12</td>
<td>2006</td>
<td>Cameroon</td>
<td>Descriptive</td>
<td>Unknown</td>
<td>Man:52.0% 108 HIV-infected patients with herpes zoster</td>
<td></td>
</tr>
<tr>
<td>Viroj13</td>
<td>2004</td>
<td>Thailand</td>
<td>Descriptive</td>
<td>Unknown</td>
<td>Man:52.0% 11 HIV-infected patients with herpes zoster</td>
<td></td>
</tr>
</tbody>
</table>

(Continued)
### Table 1 (Continued)

<table>
<thead>
<tr>
<th>Author</th>
<th>Year</th>
<th>Area</th>
<th>Type</th>
<th>Mean Age/Gender</th>
<th>Population</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marshall</td>
<td>2004</td>
<td>America</td>
<td>Cohort</td>
<td>36.8 (7.8) Woman:100%</td>
<td>337 HIV-infected patients with herpes zoster</td>
<td>Reference (CD4 =750) CD4 &lt;200: OR=3.16 (95% CI 1.92–5.18) CD4 200–349: OR=2.72 (95% CI 1.66–4.46) CD4 350–499: OR=2.07 (95% CI 1.27–3.38) CD4 500–749: OR=1.43 (95% CI 0.86–2.37)</td>
</tr>
<tr>
<td>Dilys</td>
<td>2000</td>
<td>Uganda</td>
<td>Prospective</td>
<td>31.2 Man: 51.3%</td>
<td>251 HIV-infected patients, 231 negative participants</td>
<td>Reference (CD4&gt;500) CD4 0–199: RR=2.01 (0.76–5.30) CD4 200–499: RR=0.80 (0.11–5.98)</td>
</tr>
<tr>
<td>Anna</td>
<td>1997</td>
<td>Australia</td>
<td>Retrospective</td>
<td>32 Man:100%</td>
<td>146 HIV-infected patients, of which 30 developed herpes zoster</td>
<td>CD4 between individuals with and without herpes zoster (P&gt;0.05)</td>
</tr>
</tbody>
</table>

### Table 2 The Cases of the HIV-Infected Patients with Herpes Zoster

<table>
<thead>
<tr>
<th>Author</th>
<th>Year</th>
<th>Area</th>
<th>Type</th>
<th>Mean Age/Gender</th>
<th>Population</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Catherine</td>
<td>2020</td>
<td>America</td>
<td>Case</td>
<td>53 Woman</td>
<td>1 HIV-infected patients with disseminated herpes zoster</td>
<td>CD4&lt;200</td>
</tr>
<tr>
<td>Pooja</td>
<td>2008</td>
<td>America</td>
<td>Case series</td>
<td>Case1:40, Man Case2:56, Man Case3:26, Man</td>
<td>3 HIV-infected patients with disseminated herpes zoster</td>
<td>Case1: CD4=762 Case2: CD4=420 Case3: CD4=540 CD4=191</td>
</tr>
<tr>
<td>Catarina</td>
<td>2022</td>
<td>Portugal</td>
<td>Case</td>
<td>43 Woman</td>
<td>1 HIV-infected patients with herpes zoster</td>
<td>CD4=455</td>
</tr>
<tr>
<td>Ermira</td>
<td>2022</td>
<td>Albania</td>
<td>Case</td>
<td>47 Man</td>
<td>1 HIV-infected patients with disseminated herpes zoster</td>
<td>CD4=171</td>
</tr>
<tr>
<td>Rohit</td>
<td>2010</td>
<td>India</td>
<td>Case</td>
<td>29 Woman</td>
<td>1 HIV-infected patients with herpes zoster ophthalmicus</td>
<td>CD4=245</td>
</tr>
<tr>
<td>Rachel</td>
<td>2017</td>
<td>America</td>
<td>Case</td>
<td>31 Woman</td>
<td>1 HIV-infected patients with herpes zoster</td>
<td>CD4=245</td>
</tr>
</tbody>
</table>

(Continued)
common in human immunodeficiency virus (HIV) positive patients compared to the general population. Bong et al.\textsuperscript{30} reported that a 51-year-old man had segmental vesicles on his left upper trunk and arm and a varicella like rash on his whole body. He was diagnosed with disseminated herpes zoster, and then he was found to be HIV positive. John et al.\textsuperscript{28} reported a case of HIV infected pregnant woman with disseminated herpes zoster as the initial manifestation.

**Conclusion**

In this case, the patient has disseminated herpes zoster, accompanied by ulcers, pustules, and blood crust, and the value of CD4$^+$ T cells is 379 cells/mm$^3$ (16.49%). Subsequently, he was tested positive for HIV. In conclusion, if the CD4 level of herpes zoster patients decreases and certain skin manifestations develop, such as disseminated, ulcerative, or pustular lesions, it is necessary to screen for HIV.

**Consent**

We had obtained the patient’s written informed consent for the publication of this paper and the accompanying images. This case does not require institutional approval.

**Disclosure**

There is no conflict of interest in this work.

**References**


